Medicxi Ventures Management (Jersey) Ltd
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed January 23, 2025), Medicxi Ventures Management (Jersey) Ltd reported 5 stock positions worth $529.0 million. Its top holding was Centessa Pharmaceuticals (CNTA) at 63.2% of the portfolio, followed by Newamsterdam Pharma (NAMS, 13.9%) and Phathom Pharmaceuticals (PHAT, 11.5%). Compared with Q3 2024, it opened 1 new position. The biggest buy was a new position in Rapt Therapeutics.
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001715579
- Portfolio Value
- $529.0M (Q4 2024)
- SEC Filing
- 0000950123-25-000517 ↗ filed Jan 23, 2025
Holdings Value
Holdings 5 stocks · $529.0M
| CNTA Centessa Pharmaceuticals Ltd. | 63.20% | 19,963,157 | $334.4M | No change |
| NAMS Newamsterdam Pharma Co. NV | 13.94% | 2,869,565 | $73.7M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 11.46% | 7,464,572 | $60.6M | No change |
| RAPT THERAPEUTICS INC | 6.68% | 22,352,000 | $35.3M | New |
| AURA Aura Biosciences Inc. | 4.72% | 3,039,892 | $25.0M | No change |
Portfolio Sells Q3 2024 → Q4 2024
| None this quarter. | |||
Portfolio Buys Q3 2024 → Q4 2024
| RAPT THERAPEUTICS INC | New | 6.68% | +6.68 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 3 | $177.4M | PHAT, NAMS, AURA |
| Q1 2026 | 4 | $981.8M | CNTA, NAMS, PHAT, AURA |
| Q4 2025 | 5 | $835.0M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q3 2025 | 5 | $744.4M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q2 2025 | 5 | $427.3M | CNTA, PHAT, NAMS, RAPT, AURA |
| Q1 2025 | 5 | $437.7M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q4 2024 | 5 | $529.0M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q3 2024 | 4 | $528.9M | CNTA, PHAT, NAMS, AURA |
| Q2 2024 | 4 | $335.3M | CNTA, PHAT, NAMS, AURA |
| Q1 2024 | 5 | $449.2M | CNTA, PHAT, NAMS, MRUS, AURA |